Literature DB >> 29699830

Prevalence and risk factors for low bone mineral density in antiretroviral therapy-naive HIV-infected young men.

J Paccou1, N Viget2, E Drumez3, B Cortet4, O Robineau5.   

Abstract

OBJECTIVE: We aimed to investigate the prevalence of low bone mineral density (BMD) and associated factors in antiretroviral therapy (ART)-naive HIV-infected young men.
METHODS: In this cross-sectional study, dual-energy X-ray absorptiometry (DXA) was used to measure BMD. BMD at the lumbar spine, total hip and femoral neck sites was expressed as a Z-score (number of standard deviations away from the mean in an age, race and sex-matched reference population). Low BMD was defined as Z-scores≤-2 at any of the three sites. The prevalence of low BMD was evaluated at the lumbar spine, total hip and femoral neck sites, as were risk factors associated with Z-scores.
RESULTS: The study cohort comprised 49 men, of whom 87.8% were white. Mean age was 31.6 (±7.7) years and mean BMI was 22.7 (±4.0)kg/m2. Half of patients (51.0%) were current smokers. The prevalence of low BMD was 24.5% [95% CI, 13.3-38.9]. Low estradiol levels and low BMI were associated with low Z-scores at each skeletal site, whereas current smoking and high IGF1 levels were associated with low Z-scores at the lumbar spine site. Among the HIV-related factors, low CD4+ cell count was associated with low Z-scores at the lumbar spine site.
CONCLUSIONS: We observed a high prevalence of low BMD in our ART-naive cohort of young men. Risk factors associated with low Z-scores were those usually observed in HIV-infected individuals (low BMI, current smoking and CD4+ cell count) or linked to endocrine hormone levels (estradiol, IGF-1).
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Antiretroviral therapy; Bone mineral density; Densité minérale osseuse; HIV; Traitement antirétroviral; VIH

Mesh:

Substances:

Year:  2018        PMID: 29699830     DOI: 10.1016/j.medmal.2018.02.009

Source DB:  PubMed          Journal:  Med Mal Infect        ISSN: 0399-077X            Impact factor:   2.152


  4 in total

1.  Lactobacillus rhamnosus GG attenuates tenofovir disoproxil fumarate-induced bone loss in male mice via gut-microbiota-dependent anti-inflammation.

Authors:  Hao Liu; Ranli Gu; Wei Li; Wen Zhou; Zhe Cong; Jing Xue; Yunsong Liu; Qiang Wei; Yongsheng Zhou
Journal:  Ther Adv Chronic Dis       Date:  2019-07-03       Impact factor: 5.091

2.  Increased risk factors associated with lower BMD in antiretroviral-therapy-naïve HIV-infected adult male.

Authors:  Patricia Atencio; Alfonso Cabello; Aránzazu Mediero; Miguel Górgolas; Francisco M Conesa-Buendía; Ramón Pérez-Tanoira; Laura Prieto-Pérez; Irene Carrillo; Beatriz Álvarez; Rosa Arboiro-Pinel; Manuel Díaz-Curiel; Gabriel Herrero-Beaumont
Journal:  BMC Infect Dis       Date:  2021-06-09       Impact factor: 3.090

3.  Bone Mineral Content Estimation in People Living with HIV: Prediction and Validation of Sex-Specific Anthropometric Models.

Authors:  Igor Massari Correia; Anderson Marliere Navarro; Jéssica Fernanda Corrêa Cordeiro; Euripedes Barsanulfo Gonçalves Gomide; Lisa Fernanda Mazzonetto; Alcivandro de Sousa Oliveira; Emerson Sebastião; Bruno Augusto Aguilar; Denise de Andrade; Dalmo Roberto Lopes Machado; André Pereira Dos Santos
Journal:  Int J Environ Res Public Health       Date:  2022-09-28       Impact factor: 4.614

4.  Bone Deleterious Effects of Different NRTIs in Treatment-naïve HIV Patients After 12 and 48 Weeks of Treatment.

Authors:  Patricia Atencio; Francisco Miguel Conesa-Buendía; Alfonso Cabello-Ubeda; Patricia Llamas-Granda; Ramón Pérez-Tanoira; Laura Prieto-Pérez; Beatriz Álvarez Álvarez; Irene Carrillo Acosta; Rosa Arboiro-Pinel; Manuel Díaz-Curiel; Raquel Largo; Gabriel Herrero-Beaumont; Miguel Górgolas; Aránzazu Mediero
Journal:  Curr HIV Res       Date:  2021       Impact factor: 1.341

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.